Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vanda Pharmaceuticals Inc. Director's Dealing 2024

Jul 29, 2024

33390_dirs_2024-07-29_79e8cc92-4de2-4a37-8eae-b8e20bc57dae.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2024-07-29

Reporting Person: Moran Kevin Patrick (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-07-29 Common Stock S 2251 $5.9203 Disposed 228763 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 635 Indirect

Footnotes

F1: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default "same day sale" provisions of the RSU agreements.